Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoramidis in Symptomatic ATTR-PN (ATTRibute-PN)
NCT04882735Phase 3Withdrawn
- Sponsor
- BridgeBio Pharma
- Start
- Sep 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of acoramidis in transthyretin amyloid polyneuropathy (ATTR-PN), sponsored by BridgeBio Pharma. Planned start Sep 2021; status: withdrawn.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloid polyneuropathy (ATTR-PN)
Beyond the preview
Go deeper on NCT04882735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882735.